Evidence map›Paper›PMID 32964203›Full record

ArticleKidney medicine

Uric Acid Lowering and Biomarkers of Kidney Damage in CKD Stage 3: A Post Hoc Analysis of a Randomized Clinical Trial.

Loni Perrenoud, Nicholas T Kruse, Emily Andrews, Zhiying You, Michel Chonchol, Chaorong Wu, Patrick Ten Eyck, Diana Zepeda-Orozco, Diana Jalal

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01228903 (Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?), which is not on this map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01228903 nacompletednot on this map

Is Uric Acid a Mediator of Endothelial Dysfunction in Patients With Chronic Kidney Disease?

TypeinterventionalSponsorUniversity of Colorado, DenverRan2010 to 2016Enrolled80ConditionsKidney DiseaseArmsAllopurinol, Placebo
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Loni PerrenoudDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Nicholas T KruseDivision of Nephrology, Department of Internal Medicine, Carver College of Medicine, Iowa City, IA.
Emily AndrewsDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Zhiying YouDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Michel ChoncholDivision of Renal Diseases and Hypertension, Department of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.
Chaorong WuInstitute for Clinical and Translational Science, University of Iowa, Iowa City, IA.
Patrick Ten EyckInstitute for Clinical and Translational Science, University of Iowa, Iowa City, IA.
Diana Zepeda-OrozcoDivision of Pediatric Nephrology, Dialysis and Transplantation, Stead Family Department of Pediatrics, University of Iowa, Iowa City, IA.
Diana JalalDivision of Nephrology, Department of Internal Medicine, Carver College of Medicine, Iowa City, IA.
University of Colorado Anschutz Medical Campus · USUniversity of Iowa · US

Funding

The University of Iowa Clinical and Translational Science AwardUL1TR002537 · NCATS · UNIVERSITY OF IOWA · PI HANSEN, MARLAN R, WINOKUR, PATRICIA · 2018 to 2022
$20.0M
Curcumin Supplementation for Improving Vascular and Cognitive FunctionR01HL134738 · NHLBI · UNIVERSITY OF IOWA · PI JALAL, DIANA I · 2017 to 2020
$2.3M
Uric Acid as a Mediator of Endothelial Dysfunction in Patients with CKDK23DK088833 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI JALAL, DIANA I · 2010 to 2014
$897k
NCATS NIH HHS UL1 TR002537NHLBI NIH HHS R01 HL134738NIDDK NIH HHS K23 DK088833
6 · The paper itself

Abstract

RATIONALE &

objectiveHyperuricemia is associated with chronic kidney disease (CKD) progression. We evaluated whether lowering serum uric acid levels improves levels of biomarkers of kidney damage. STUDY

designPost hoc analysis of clinical trial participants. SETTING &

participantsA double-blind randomized placebo-controlled study designed to lower serum uric acid levels. 80 patients with stage 3 CKD and asymptomatic hyperuricemia were randomly assigned to allopurinol treatment or placebo (300 mg/d) for 12 weeks. EXPOSURE/PREDICTOR: Allopurinol treatment versus placebo. OUTCOMES & MEASURES: We evaluated the change from baseline for the following urinary biomarkers of kidney damage: albumin-creatinine ratio (ACR), neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule 1 (KIM-1), and transforming growth factor β1 (TGF-β1). Additionally, we evaluated CKD Epidemiology Collaboration (CKD-EPI)-estimated glomerular filtration rate (eGFR) and cystatin C eGFR. ANALYTICAL APPROACH: Generalized linear mixed modeling was used.

resultsAfter 12 weeks, allopurinol (compared to placebo) significantly lowered serum uric acid levels with an estimate of -3.3 mg/dL (95% CI, -4.1 to -2.5 mg/dL; LIMITATIONS: Post hoc analysis and short duration of the study.

conclusionsUric acid-lowering with allopurinol is not associated with improvement in levels of biomarkers of kidney damage in patients with asymptomatic hyperuricemia and stage 3 CKD.

fundingThe study was funded by the National Institutes of Health through a career development award, K23DK088833, and the Clinical and Translational Science Award UL1TR002537.

trial registrationNCT01228903.

Indexed as

allopurinolChronic kidney diseasekidney damagekidney functionuric acid

Identifiers

PMID32964203
PMCPMC7487946
OpenAlexW3005535800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.